2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
1
Opportunistic Infections
1
Inflammation
1
Hepatitis B, Chronic
1
Hepatitis B
1
Heartburn
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Carcinoma, Hepatocellular
1
Acquired Immunodeficiency Syndrome
1
Interventions
Valganciclovir
4
Polymerase Chain Reaction
3
Flow Cytometry
3
Blood Specimen Collection
3
Valacyclovir
2
Ganciclovir
2
Cell Count
2
letermovir
1
dolutegravir
1
Zidovudine
1
VCL-CB01 vaccine
1
Therapeutics
1
Stem Cell Transplantation
1
Specimen Handling
1
Ritonavir
1
Peripheral Blood Stem Cell Transplantation
1
Nucleosides
1
Magnetic Resonance Spectroscopy
1
Immunologic Techniques
1
Gene-Eden-VIR
1
Foscarnet
1
Darunavir
1
Antiviral Agents
1
Acyclovir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cytomegalovirus Infections
×
Nucleosides
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn